THE SPECTRUM OF CO-MORBIDITIES IN CHILDREN WITH ASD (AUTISM SPECTRUM DISORDER): **A RETROSPECTIVE STUDY**





¹Sheffali Gulati; ¹Kakali Purkayastha; ¹Gautam Kamila; ¹Arvinder Wander; ¹Sayoni Roy Chowdhury; ¹Ankit Kumar Meena, ²Sonali Singh; ³Juhi Gupta; ¹Sanjeeda Khan; ¹Arunangshu Bhattacharyya; ¹Shobha Sharma; ¹Anushka Rathi ¹Centre Of Excellence and Advanced Research for Childhood Neurodevelopmental Disorders, Child Neurology Division, Department of Paediatrics, Child Neurology Division, Department of Paediatr All India Institute of Medical Sciences, New Delhi, India; ²Institute of Neurosciences, Kolkata, India; 3Department of Pediatrics, SMS Medical College & Hospital, Jaipur, India (Corresponding Author: sheffaligulati@gmail.com)

INTRODUCTION

- Estimates from the CDC's Autism and Developmental Disabilities Monitoring Network - about 1 in 44 children
- INCLEN study (2011) prevalence of ASD around 1 in 89 children.
- It not only affects the life of the affected individual, but also their immediate caregivers, families, and society
- In addition to the core ASD symptoms, children with ASD may present with additional comorbidities - identifying these conditions is essential, as most could exacerbate or stimulate the behavioral abnormalities in these children
- Appropriate management of these comorbidities improves the child's behavior – May point to an underlying pathomechanism requiring a more advanced approach to treatment
- Occurrence of comorbidities may contribute to increased risk of mortality associated with ASD - treatment of comorbidities in these children could lead to a significant betterment of their quality of life
- Co-occurrence patterns among co-morbidities in ASD may help to uncover the underlying etiologies associated with ASD Most of these comorbid conditions are treatable

OBJECTIVES

To study the spectrum of co-morbidities in children with ASD

100% ASD population presentation in our center 80% ASD population with co-morbidities 35% ASD population with >one co-morbidities Fig 1: Proportion of children with comorbidities [Table 1]

METHODOLOGY

Retrospective Study of patients between January 2017 to March 2021 Study population: Children attending to the Autism Clinic, Child Neurology Division, AIIMS, New Delhi Inclusion criteria:

Children aged 2-18 years, with ASD (DSM 5 criteria) 2. Parental consent Exclusion criteria:

Parents unwilling for participation

Detailed history from parents was obtained using a standard clinical proforma

Evaluation for symptom severity and behavioural co-morbidities were done by CARS, Autism Behaviour Checklist (ABC), and Childhood Behaviour Check List (CBCL)


Based on the co-morbidities and severity the standard form of behavioural therapy and medications were prescribed - children were followed in Autism clinic at 1-3 monthly intervals

RESULTS

1872 children [1582 males (84.5%); 290 females (15.5%); Median age: 5.6 years(IQR: 5.1 - 8.5 years) Proportion of children with comorbidities - 80% (1499/1872); 35% had more than one comorbidity [Fig 1] Attention deficit hyperactivity disorder - most common behavioural comorbidity (57.55%), followed by disruptive behaviour (4.51%) and obsessive-compulsive disorder (1.42%) - 62% of the children had a psychiatric comorbidity

Among systemic abnormalities, neurological comorbidities (global developmental delay/intellectual disability, sleep abnormalities, epilepsy, isolated speech/language delay and sensory processing disorder) were most common (52.6%) - Mean duration of follow-up - 28.9 +/- 11.46 months [Fig 2 - 4]

Post-behavioural therapy on follow-up, significant (p<0.0001) improvement in core features was observed as</p> measured by mean CARS score. Significantly high ABC scores were observed in patients with speech/language delay, specific learning disability, sensory processing disorder, wandering & genetic disorder



GENETIC/METABOLIC DISORDERS

Fig 4: Diversity of genetic/metabolic disorders

Table 1 - Outcome of behavioral therapy in children with As				
Total patients	Severity of ASD		Mean CARS	ſ
(N = 1872)	Mild to moderate	Severe	score (± 2SD)	SC
	(CARS ≤ 37)	(CARS > 37)		
Pre-therapy	1074	798	36.92 ± 5.00	83
Post-therapy	1486	386	34.27 ± 4.07	73
p-value	< 0.001		<0.0001	<0

CONCLUSIONS

- The presence of comorbidities seen in 80% of the patients did not affect the severity of ASD
- Post-therapy, significant improvement in their functional outcome was observed
- A holistic scrupulous approach is necessary for best outcome

REFERENCES

- Aathira, R., Gulati, S., Tripathi, M., Shukla, G., Chakrabarty, B., Sapra, S., Dang, N., Gupta, A., Kabra, M., & Pandey, R. M. (2017). Prevalence of Sleep Abnormalities in Indian Children With Autism Spectrum Disorder: A Cross-Sectional Study. Pediatric Neurology, 74, 62–67
- 2. Verma, V., Paul, A., Amrapali Vishwanath, A., Vaidya, B., & Clement, J. P. (n.d.). Understanding intellectual disability and autism spectrum disorders from common mouse models: Synapses to behaviour. Open Biology, 9(6), 180265
- Sivertsen, B., Posserud, M.-B., Gillberg, C., Lundervold, A. J., & Hysing, M. (2012). Sleep problems in children with autism spectrum problems: A longitudinal population-based study. Autism: The International Journal of Research and Practice, 16(2): 139–150

CONTACT

Prof. Sheffali Gulati - sheffaligulati@gmail.com



